Exploratory endpoint
tumor
TUMOR, INFILTRATES

Immunohistology for PDL1 (Sp142 and 22C3), TIGIT, CD155, and CD112Immunohistology before treatment and after 2 months of therapy to study immune infiltrates (PDL1, CD112, CD155, CD8, CD19, DC-Lamp, TCF1, CD163) using multiplex immune histology and spatial transcriptomic profiling for a sample of good responders or stable and poor responders (progressing straight away)Study of peripheral immune response upon multiparametric cytometry and multiplex cytokine testing at baseline and following treatmentStudy of a specific peripheral immune response against two shared antigens (telomerase and NY-ESO1) on isolated peripheral blood mononuclear cells (PMBC). Telomerase and NY-ESO1-specific T-cell responses will be assessed by a standardized IFN-γ ELISPOT assay.Neopeptide detection upon exome sequencingStudy of the impact of the total volume receiving the prescribed dose on specific tumor immune response